This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results
by Zacks Equity Research
HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
AMN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.
Bet on Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Varian (VAR) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment in fiscal Q1.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.
Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall
by Zacks Equity Research
Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.
Here's Why You Should Add HealthEquity (HQY) to Portfolio Now
by Zacks Equity Research
Solid prospects in the HSA industry consistently drive HealthEquity (HQY).
Here's Why You Should Invest in Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.
HealthEquity (HQY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed the most recent trading day at $70.58, moving -1.64% from the previous trading session.
Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid international show in Q4.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.
Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?
by Sapna Bagaria
Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) expects its strong product portfolio to consistently drive top line.
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Allscripts Expands Partnership With PIH Health Through 2025
by Zacks Equity Research
Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.
Inogen (INGN) Announces Preliminary Q4 Results, Slashes View
by Zacks Equity Research
Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.
ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View
by Zacks Equity Research
ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.